Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal remimazolam besylate premedication in children undergoing tonsillectomy/adenoidectomy
ChiCTR2400086998Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Ningbo University
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of remimazolam in Tonsillar hyperplasia and adenoidal hypertrophy (2 arms), sponsored by First Affiliated Hospital of Ningbo University. Primary endpoint: Perioperative Respiratory Adverse Events. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
Tonsillar hyperplasiaadenoidal hypertrophy
Beyond the preview
Go deeper on ChiCTR2400086998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086998.